A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2026-05-01

Summary

To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib

• Phase: PHASE2

Details

• Lead Sponsor: Huihua Xiong